JAK2 and neoplasm: Patients with PCM1‐JAK2 fusion can be diagnosed as “myeloid/lymphoid neoplasms with PCM1‐JAK2”, which is now incorporated into the 2016 revision of WHO classification of neoplastic diseases of the hematopoietic and lymphoid tissues as a provisional entity (Arber et al., 2016).